|Fastest Growing Market:||Asia-Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The immunomodulators market is expected to register a CAGR of 5.4% over the forecast period 2022-2027.
The coronavirus disease (COVID-19) pandemic has affected the market for immunomodulators adversely. The article “COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs” published in 2022, by the British Journal of Ophthalmology, explains that immune suppressants have been widely used by doctors to treat chronic inflammatory illnesses, it does come with a few drawbacks, one of which is an increased risk of infection. Additionally, tt is crucial that doctors should properly give instructions to patients while taking medications considering the present COVID-19 outbreak. Hence, the market of immunomodulators has been impacted during the COVID outbreak.
Further, the increasing rate of diseases post covid caused the immunomodulator market to grow at a faster pace. The article “Immunotherapies and immunomodulatory approaches in clinical trials - a mini review” published in the Human Vaccines & Immunotherapeutics journal in 2021, reveals that due to the respiratory issues developed after covid in many patients despite age group lead to the rise of immunotherapies when there was limited availability of vaccines. Immunotherapies employing convalescent plasma, immunoglobulins, antibodies (monoclonal or polyclonal), and the use of immunomodulatory agents to boost immunity are valuable alternatives due to the lack of any vaccine or medicines against COVID-19.
Increasing Incidence of Chronic Diseases Such as Asthma, Allergic Conditions, Cancer, and Multiple Sclerosis causes the immunomodulators market to grow, for instance, the research published in American Cancer Society points out that because of population expansion and ageing, it is anticipated that by 2040 there would be 16.3 million cancer deaths and 27.5 million new cancer cases worldwide. Due to the rising frequency of risk factors like smoking, poor food, and physical inactivity in economically developing nations, the burden will likely grow in the future.
Furthermore, market players are engaged in marketing tactics such as mergers and acquisitions, as well as product launches for instance in October 2019, Pandion Therapeutics, Inc. and Astellas Pharma Inc. signed a license and collaboration agreement to collaborate on the discovery, production, and marketing of locally acting immunomodulators for pancreatic autoimmune disorders. For the treatment of autoimmune conditions, the agreement will allow the parties to integrate Pandion's modular biologics and functional immunology knowledge with Astellas' advanced medicines development and worldwide marketing expertise.
The evaluated market is expected to grow throughout the analysis period for the reasons stated. However, unfavorable regulatory policies limit the growth of the immunomodulators industry.
Scope of the Report
As per the scope of the report, immunomodulators are the agents that can enable the body fight cancer, infection, or other disorders by stimulating or suppressing the immune system. The immunomodulators market is segmented by Product Type (Immunosuppressants, Immunostimulants, Other Product Types), Application (Oncology, Respiratory, HIV, Other Applications) End Users (Hospitals, Clinics & Other End Users), Geography (North America, Europe, Asia-Pacific, South America, Middle East, and Africa). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
|By Product Type|
|Other Product Types|
|Other End Users|
Key Market Trends
Immunosuppressants are Expected to Witness a Positive Growth Over the Forecast Period
Immunosuppressive drugs, often known as immunosuppressive agents, are medications that inhibit or block immune system activation. It can reduce the high reactivity of the immune system which is causing auto-immune diseases and other chronic disorders.
An article published in PubMed in 2021, “Systematic review of immunosuppressant guidelines in the COVID-19 pandemic”, explains that Immunosuppressants, such as corticosteroids, cytokine-targeted therapies, monoclonal antibodies, and antimetabolites, are commonly prescribed for inflammatory bowel disease (IBD), rheumatological, neurological, and dermatological conditions, as well as to prevent solid organ rejection in transplant recipients. The same source points out that Immunosuppressant use is difficult to quantify; nevertheless, in the United States, it is estimated to be between 2.7 and 6.2 percent.
The case study published in May 2021 in Clinical Case Reports under the title “Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID‐19 outbreak?” points out the fact that patients for whom intravenous immunoglobulin (IVIG) is contraindicated, cyclosporine is an effective and safe immunosuppressant alternative in the management of toxic epidermal necrolysis (TEN) during the COVID19 outbreak.
The article “Cancer and Immunosuppression” published in 2021, says that Immunotherapeutic approaches and immune-suppressing agents have recently been discovered to be effective in the treatment of cancer. Immuno-cancer vaccines and immune growth against oncological viruses are among the ongoing research projects. Control and chemopreventive medicines are non-toxic drugs that control or eradicate immunosuppression in the tumor microenvironment to prevent tumor growth. These compounds will aid in the discovery of how cancers evade treatment and the development of treatment options.
Hence, owing to the above-mentioned facts there will be a definite amount of demand for immunosuppressants in the coming years.
To understand key trends, Download Sample Report
North America is Expected to Lead the Immunomodulators Market
North America witnessed the largest lead in the Immunomodulator market in 2021. This is due to the increased prevalence of autoimmune diseases as well as enhanced trials and studies for the immunomodulatory field. According to a report published by the National Multiple Sclerosis Society in September 2020, there are 2.8 million people worldwide who have multiple sclerosis, and more than 1 million reside in the United States alone.
Key product releases and the presence of manufacturers in the country are all factors that have contributed to the growth of the immunomodulators market. According to the press release in December 2020, With the launch of Tacrolimus capsules in the United States, Biocon expands its generic formulation offering. Tacrolimus, a calcineurin inhibitor, is an immunosuppressant that inhibits the body's ability to eliminate a donated organ in organ transplant patients. For more than two decades, it has proven to be particularly successful in the treatment of renal transplant patients.
Furthermore, increased efforts for the developments in immunomodulation fields lead the market to grow in North America. According to the studies published by National Institute of Health in October 2020, explains that large clinical trials are started to test immune modulators for the treatment of COVID-19. The goal of the clinical research is to see if reducing the need for ventilators and shortening hospital stays can be accomplished by regulating the immune response. The ACTIV-1 Immune Modulators (IM) trial will be demonstrating if the medicines can stabilize the overactive immune system into normal. As a result of the preceding reasons, the studied market is expected to increase in the North America.
To understand geography trends, Download Sample Report
The immunomodulators market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known. include Pfizer Inc., Acrotech Biopharma, LLC, Astellas Pharma Inc., Horizon Therapeutics plc, and Petrovax among others.
In January 2022, Sun Pharma launched a dry eye treatment product in Canada named CEQUA, a calcineurin inhibitor immunomodulator, that uses nano micellar (NCELL) technology to improve the bioavailability and physicochemical stability of cyclosporine to promote the ocular tissue penetration.
In February 2021 Merck announced the acquisition of Pandion Therapeutics in which the acquisition adds the pipeline of candidates targeting a broad range of Autoimmune Diseases. Pandion has used its TALON technology to build a strong pipeline of candidates that aim to regulate the immune response and could be used to treat a variety of autoimmune conditions.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Chronic Diseases Such as Asthma, Allergic Conditions, Cancer, and Multiple Sclerosis
4.2.2 Emergence of Research and Development in the Field of Immunomodulators
4.3 Market Restraints
4.3.1 Adverse Effect of Drugs
4.3.2 Unfavourable Regulatory Policies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product Type
5.1.3 Other Product Types
5.2 By Application
5.2.4 Other Applications
5.3 By End-User
5.3.3 Other End Users
5.4.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.4.4 Middle East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle East and Africa
5.4.5 South America
220.127.116.11 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.2 Avidea Technologies
6.1.4 InDex Pharmaceuticals Holding AB
6.1.5 Pfizer Inc
6.1.7 Horizon Therapeutics plc
6.1.8 Acrotech Biopharma, LLC
6.1.9 Astellas Pharma Inc.
6.1.10 Bristol-Myers Squibb Company
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Immunomodulators Market market is studied from 2019 - 2027.
What is the growth rate of Global Immunomodulators Market?
The Global Immunomodulators Market is growing at a CAGR of 5.4% over the next 5 years.
Which region has highest growth rate in Global Immunomodulators Market?
Asia-Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Immunomodulators Market?
North America holds highest share in 2021.
Who are the key players in Global Immunomodulators Market?
Pfizer Inc, Horizon Therapeutics plc., Astellas Pharma Inc., Acrotech Biopharma, LLC, Petrovax are the major companies operating in Global Immunomodulators Market.